Lipimetix Development Inc., of Natick, Mass., said Anji Pharmaceuticals Inc., of China, entered a licensing deal for the Lipimetix platform of peptides (AEM-28 and analogues) for development in mainland China, Taiwan and Hong Kong. Terms include an up-front payment of $2 million, multiple additional cash payments upon achievement of clinical/regulatory milestones and a royalty on Anji Pharma's future pharmaceutical revenues derived from the program.